GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Echo Therapeutics Inc (OTCPK:ECTE) » Definitions » Current Ratio

Echo Therapeutics (Echo Therapeutics) Current Ratio : 0.06 (As of Sep. 2016)


View and export this data going back to 1997. Start your Free Trial

What is Echo Therapeutics Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Echo Therapeutics's current ratio for the quarter that ended in Sep. 2016 was 0.06.

Echo Therapeutics has a current ratio of 0.06. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Echo Therapeutics has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Echo Therapeutics's Current Ratio or its related term are showing as below:

ECTE's Current Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.715
* Ranked among companies with meaningful Current Ratio only.

Echo Therapeutics Current Ratio Historical Data

The historical data trend for Echo Therapeutics's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Echo Therapeutics Current Ratio Chart

Echo Therapeutics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.84 0.54 2.57 0.59 0.09

Echo Therapeutics Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.09 0.07 0.13 0.06

Competitive Comparison of Echo Therapeutics's Current Ratio

For the Medical Devices subindustry, Echo Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Echo Therapeutics's Current Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Echo Therapeutics's Current Ratio distribution charts can be found below:

* The bar in red indicates where Echo Therapeutics's Current Ratio falls into.



Echo Therapeutics Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Echo Therapeutics's Current Ratio for the fiscal year that ended in Dec. 2015 is calculated as

Current Ratio (A: Dec. 2015 )=Total Current Assets (A: Dec. 2015 )/Total Current Liabilities (A: Dec. 2015 )
=0.301/3.235
=0.09

Echo Therapeutics's Current Ratio for the quarter that ended in Sep. 2016 is calculated as

Current Ratio (Q: Sep. 2016 )=Total Current Assets (Q: Sep. 2016 )/Total Current Liabilities (Q: Sep. 2016 )
=0.402/7.267
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Echo Therapeutics  (OTCPK:ECTE) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Echo Therapeutics Current Ratio Related Terms

Thank you for viewing the detailed overview of Echo Therapeutics's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Echo Therapeutics (Echo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
99 Wood Avenue South, Suite 302, Iselin, NJ, USA, 08830
Echo Therapeutics Inc is a medical device company with expertise in skin permeation technology. It develops non-invasive, wireless continuous glucose monitoring system with potential use in the wearable health consumer and the diabetes outpatient market.
Executives
Michael M Goldberg director C/O MONTAUR CAPITAL PARTNERS, 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Uri Landesman 10 percent owner 230 PARK AVENUE, NEW YORK NY 10169
Platinum Partners Value Arbitrage Fund, Lp 10 percent owner 250 WEST 55TH STREET, 14TH FLOOR, NEW YORK NY 10019
Mark Nordlicht 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Platinum Management (ny) Llc 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Platinum-montaur Life Sciences, Llc 10 percent owner 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Platinum Partners Liquid Opportunity Master Fund L.p. 10 percent owner 152 WEST 57 STREET, 4TH FLOOR, NEW YORK NY 10019
Platinum Liquid Opportunity Management (ny) Llc 10 percent owner 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Bernhardt Charles Thomas Iii officer: Interim CFO 23 BIRCH ROAD, MALVERN PA 19355
Vincent D Enright director ONE CORPORATE CENTER, RYE NY 10580
William Grieco director 830 CRESCENT CENTRE DRIVE, SUITE 610, FRANKLIN TN 37067
Platinum Long Term Growth Vii, Llc 10 percent owner 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Robert F Doman director, officer: EXEC. CHAIRMAN AND INTERIM CEO C/O DUSA PHARMACEUTICALS, INC., 25 UPTON DRIVE, WILMINGTON MA 01887
Patrick T Mooney director, officer: CEO AND PRESIDENT C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
Christopher P. Schnittker officer: CFO 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540

Echo Therapeutics (Echo Therapeutics) Headlines

No Headlines